

## *Supplementary Material*

### Supplementary Tables

**Supplementary TableS1:** Baseline data for KIRC patients

Characteristics	Expression of MTF1		P value
	Low	High	
Age <sup>a</sup> , N=539	269	270	0.282
<= 60	128 (23.7%)	140 (26.0%)	
> 60	141 (26.2%)	130 (24.1%)	
Gender, N=539	269	270	<b>0.006</b>
Male	191 (35.4%)	161 (29.9%)	
Female	78 (14.5%)	109 (20.2%)	
Pathologic T stage <sup>b</sup> , N=539	269	270	<b>0.001</b>
T1&T2	156 (28.9%)	192 (35.6%)	
T3&T4	113 (21.0%)	78 (14.5%)	
Pathologic N stage <sup>b</sup> , N=257	128	129	0.97
N0	120 (46.7%)	121 (47.1%)	
N1	8 (3.1%)	8 (3.1%)	
Pathologic M stage <sup>b</sup> , N=506	253	253	0.111
M0	207 (40.9%)	220 (43.5%)	
M1	46 (9.1%)	33 (6.5%)	
Pathologic stage, N=536	268	268	<b>&lt;0.001</b>
Stage I & Stage II	144 (26.9%)	186 (34.7%)	
Stage III & Stage IV	124 (23.1%)	82 (15.3%)	
Histologic grade, N=531	265	266	<b>&lt;0.001</b>
G1&G2	102 (19.2%)	146 (27.5%)	
G3&G4	163 (30.7%)	120 (22.6%)	

<sup>a</sup> Cut-off value based on previous studies.

<sup>b</sup> Diagnosed based on the AJCC, 2017 criteria (the eighth edition).

**Supplementary TableS2: Baseline data for LGG patients**


Characteristics	Expression of MTF1		P value
	Low	High	
Age <sup>a</sup> , N=509	254	255	<b>0.030</b>
<= 40	112 (22.0%)	137 (26.9%)	
> 40	142 (27.9%)	118 (23.2%)	
Gender, N=509	254	255	0.199
Female	120 (23.6%)	106 (20.8%)	
Male	134 (26.3%)	149 (29.3%)	
WHO grade <sup>b</sup> , N=452	226	226	<b>&lt;0.001</b>
G2	128 (28.3%)	89 (19.7%)	
G3	98 (21.7%)	137 (30.3%)	
Histological type, N=509	254	255	<b>&lt;0.001</b>
Oligoastrocytoma	54 (10.6%)	74 (14.5%)	
Astrocytoma	61 (12.0%)	131 (25.7%)	
Oligodendroglioma	139 (27.3%)	50 (9.8%)	
IDH status <sup>c</sup> , N=506	253	253	<b>&lt;0.001</b>
WT	28 (5.5%)	66 (13.0%)	
Mut	225 (44.5%)	187 (37.0%)	

<sup>a</sup> Cut-off value based on previous studies.


<sup>b</sup> According to the 2021 WHO classification.

<sup>c</sup> Mut: mutation, WT: wild type


## Supplementary Figures:




**Supplementary Fig. S1.** Expression of MTF1 was correlated with clinicopathological features in various cancers. **(A)** MTF1 expression was related to the stage in DLBC, KIRC, OV and THCA. **(B)** MTF1 expression was related to grade in BLCA, HNSC, KIRC, LGG and UCEC. **(C)** MTF1 expression was related to the primary therapy outcome in BLCA, DLBC, HNSC, LGG and PRAD. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .



**Supplementary Fig. S2.** Expression of MTF1 was correlated with survival across cancers. **(A)** K-M plots of OS analysis in HNSC, KIRC, LGG and READ. **(B)** K-M plots of PFS analysis in ACC, HNSC, KIRC, LGG, LUSC and SKCM. **(C)** K-M plots of DSS analysis in KIRC, LGG and LUSC.




**Supplementary Fig. S3.** MTF1 expression had diagnostic value in a variety of cancers. ROC curves in ACC (A), CHOL (B), KICH (C), LAML (D), PAAD (E), THCA (F), TGCT (G), UCEC (H), UCS (I).




**Supplementary Fig. S4.** A forest map of risk assessment for different methylation sites in KIRC, LGG, HNSC and LUSC.


### A Homozygous CNV in each cancer




### B Heterozygous CNV in each cancer




### C




### D




### E




### F



### G




### H



**Supplementary Figure S5.** CNV and methylation associated analyses of MTF1 gene. **(A)** Homozygous CNV profiles in pan-cancer. **(B)** Heterozygous CNV profiles in pan-cancer. P value of correlation analyses between survival including the OS **(C)**, PFS **(D)** and DSS **(E)** and CNV. Correlation coefficient analyses between survival including the OS **(F)**, PFS **(G)** and DSS **(H)** and methylation. \*  $P < 0.05$ , \*\*  $P < 0.01$ .



## Supplementary Figure S6



**Supplementary Fig. S6.** Correlation curves between MTF1 expression and immune cell infiltration.

Microscopic images of immunofluorescence were uploaded to this link:  
<https://www.jianguoyun.com/p/DR8dNMwQ0vfwChiMrNwEIAA> .